Completed PHASE1 INTERVENTIONAL 1-arm NCT02220049

Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors (VELDAY)

Phase I Dose Escalation of Velcade (Bortezomib) Daily Dose in Patients With Advances or Metastatic Solid Tumors

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Conditions Advanced or Metastatic Solid Tumors

Interventions Bortezomib

Updated 5 times since 2017 Last updated: Mar 24, 2016 Started: Dec 31, 2010 Primary completion: Nov 30, 2013 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced or Metastatic Solid Tumors, this trial is completed. The trial is conducted by Gustave Roussy, Cancer Campus, Grand Paris and has accumulated 5 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gustave Roussy, Cancer Campus, Grand Paris

Data source: Gustave Roussy, Cancer Campus, Grand Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Villejuif, France